Chemo-embolisation of Multifocal Hepatoma

Professor Michael C. Soulen, MD
Professor of Radiology and Surgery University of Pennsylvania Philadelphia, USA

Patient History

  • 52-year-old male with cirrhosis attributed to past alcohol abuse presented with bleeding varices that were banded.
  • MRI demonstrated two hypervascular masses measuring 5-6cm, one in left lateral segment and the other in left medial segment, surrounded by multiple small satellites.
  • Biopsy revealed moderated differentiated hepatoma.
Bead Block Case 1 fig 1

Left hepatic arteriogram: early phase

Bead Block Case 1 fig 2

Left hepatic arteriogram: late phase

 

Bead Block Case 1 fig 3

Left hepatic arteriogram: during embolisation

Procedure

  • Cobra catheter was advanced into the left hepatic artery and beyond the right gastric artery.
  • A solution of 100mg cisplatin, 50mg doxorubicin, 10mg mitomycin-C dissolved in 10ml of radiographic contrast was emulsified with 10ml of ethiodol.
  • 10-15ml of the resulting emulsion was infused slowly into the left hepatic artery.
  • One syringe of 300-500μm Bead Block™ microspheres was added to the remaining emulsion after expressing the excess saline from the syringe.
  • Careful infusion was continued until near-stasis was achieved.

Outcome

  • Angiography of left and common hepatic arteries showed no residual tumour blush.
  • Follow-up visit one month later showed complete necrosis of both masses with no viable tumour identified.
  • Complete radiographic response of multifocal hepatoma to chemo-embolisation.
Bead Block Case 1 fig 4

Arterial phase: gadolinium enhanced MRI

Bead Block Case 1 fig 5

Arterial phase: one month after chemoembolisation

 

Bead Block Case 1 fig 6

Post-embolisation: left hepatic arteriogram

Bead Block Case 1 fig 7

Post-embolisation: common hepatic arteriogram

Regulatory notices and product safety data

Worldwide (excluding USA)

Bead Block™ is CE marked and indicated for the treatment of a variety of hypervascular tumours (including Uterine Fibroids) and arteriovenous malformations (AVMs). Bead Block™ may not be indicated for the treatment of Uterine Fibroids in your country, please check with your local distributor. For full prescribing information please refer to Bead Block instructions for use.

USA

Bead Block is intended to be used for the embolization of hypervascular tumors and arteriovenous malformations (AVMs)

Bead Block Cautions:

  • Do not use if the syringe or packaging appear damaged
  • Sterile and single use product.  Do not reuse
  • Select the size and quantity of Bead Block microspheres appropriate for the pathology to be treated
  • Embolization with Bead Block microspheres should only be performed by physicians who have received appropriate interventional occlusion training in the region intended to be embolized

For instructions for use, please refer to www.biocompatibles.com/beadblock-ifu

Bead Block Potential Complications:

  • Undesirable reflux or passage of Bead Block into normal arteries adjacent to the targeted lesion or through the lesion into other arteries or arterial beds, such as the internal carotid artery, pulmonary, or coronary circulations
  • Pulmonary embolization
  • Ischemia at an undesirable location
  • Capillary bed saturation and tissue damage
  • Ischemic stroke or ischemic infarction
  • Vessel or lesion rupture and haemorrhage
  • Neurological deficits including cranial nerve palsies
  • Vasospasm
  • Death
  • Recanalization
  • Foreign body reactions necessitating medical intervention
  • Infection necessitating medical intervention
  • Clot formation at the tip of the catheter and subsequent dislodgement